Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thoracic Wall | 2 | 2018 | 24 | 1.180 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 1045 | 0.800 |
Why?
|
| Anastomotic Leak | 2 | 2021 | 108 | 0.760 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2019 | 556 | 0.730 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2022 | 88 | 0.700 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2022 | 120 | 0.690 |
Why?
|
| Diet, Western | 1 | 2019 | 42 | 0.640 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2022 | 227 | 0.640 |
Why?
|
| Mastectomy | 2 | 2018 | 257 | 0.630 |
Why?
|
| Surgical Wound Infection | 2 | 2019 | 224 | 0.590 |
Why?
|
| Colectomy | 1 | 2019 | 181 | 0.590 |
Why?
|
| Endovascular Procedures | 1 | 2022 | 309 | 0.570 |
Why?
|
| Enterocolitis | 1 | 2017 | 13 | 0.550 |
Why?
|
| Enterococcus faecalis | 4 | 2022 | 57 | 0.550 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 225 | 0.520 |
Why?
|
| Operating Rooms | 1 | 2017 | 134 | 0.500 |
Why?
|
| Infection Control | 1 | 2017 | 128 | 0.490 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 3053 | 0.450 |
Why?
|
| Lymph Nodes | 1 | 2018 | 552 | 0.450 |
Why?
|
| Sepsis | 1 | 2017 | 350 | 0.410 |
Why?
|
| Colon | 3 | 2021 | 527 | 0.400 |
Why?
|
| Postoperative Complications | 2 | 2022 | 2458 | 0.390 |
Why?
|
| Plasminogen | 2 | 2021 | 47 | 0.350 |
Why?
|
| Anastomosis, Surgical | 2 | 2020 | 280 | 0.300 |
Why?
|
| Axilla | 2 | 2018 | 105 | 0.290 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 1108 | 0.270 |
Why?
|
| Anti-Bacterial Agents | 3 | 2019 | 810 | 0.230 |
Why?
|
| Tranexamic Acid | 2 | 2021 | 40 | 0.220 |
Why?
|
| Collagen | 2 | 2021 | 303 | 0.180 |
Why?
|
| Prosthesis Design | 1 | 2022 | 303 | 0.180 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2022 | 245 | 0.170 |
Why?
|
| Collagen Type IV | 1 | 2019 | 27 | 0.160 |
Why?
|
| Organic Chemicals | 1 | 2019 | 36 | 0.160 |
Why?
|
| Fibrinolysis | 1 | 2019 | 37 | 0.160 |
Why?
|
| Collagen Type I | 1 | 2019 | 74 | 0.160 |
Why?
|
| Mice | 4 | 2022 | 12110 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 51 | 0.160 |
Why?
|
| Infliximab | 1 | 2020 | 161 | 0.160 |
Why?
|
| Stents | 1 | 2022 | 417 | 0.150 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 259 | 0.150 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2018 | 80 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2019 | 222 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2022 | 583 | 0.140 |
Why?
|
| Humans | 9 | 2022 | 92337 | 0.140 |
Why?
|
| Wound Healing | 1 | 2019 | 373 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 304 | 0.130 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2017 | 72 | 0.130 |
Why?
|
| Breast | 1 | 2018 | 289 | 0.130 |
Why?
|
| Intestines | 1 | 2019 | 424 | 0.130 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 498 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 569 | 0.130 |
Why?
|
| Bacteria | 1 | 2020 | 501 | 0.120 |
Why?
|
| Animals | 5 | 2022 | 28003 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1079 | 0.100 |
Why?
|
| Risk Factors | 1 | 2022 | 5704 | 0.090 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2022 | 52 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3775 | 0.090 |
Why?
|
| Prognosis | 1 | 2018 | 3872 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2022 | 8740 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2022 | 9703 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6916 | 0.070 |
Why?
|
| Young Adult | 1 | 2018 | 6624 | 0.060 |
Why?
|
| Adolescent | 1 | 2018 | 9504 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 2448 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 3360 | 0.050 |
Why?
|
| Collagenases | 1 | 2022 | 42 | 0.050 |
Why?
|
| Enema | 1 | 2021 | 39 | 0.050 |
Why?
|
| Microscopy, Confocal | 1 | 2021 | 283 | 0.040 |
Why?
|
| Aged | 1 | 2018 | 19943 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2021 | 207 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2019 | 41 | 0.040 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 101 | 0.040 |
Why?
|
| Proteolysis | 1 | 2019 | 122 | 0.040 |
Why?
|
| Virulence | 1 | 2019 | 277 | 0.040 |
Why?
|
| Middle Aged | 1 | 2018 | 27030 | 0.040 |
Why?
|
| Adult | 1 | 2018 | 27532 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 239 | 0.030 |
Why?
|
| Male | 1 | 2019 | 43925 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 485 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 291 | 0.030 |
Why?
|
| Phenotype | 1 | 2022 | 2498 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 400 | 0.030 |
Why?
|
| Female | 1 | 2018 | 47893 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 887 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2556 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7348 | 0.010 |
Why?
|